Loading...
Market
Which major market will first approve Gilead's STAT6 drug outside the US by 2025?
2
Resolution / Starting Odds
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
Announcements from international health agencies or Gilead Sciences
Story
Gilead Sciences Partners with LEO Pharma, Paying $250M for Oral Drug Targeting STAT6 in Inflammatory Diseases
Jan 11, 2025, 05:03 PM
Gilead Sciences has entered into a strategic partnership with LEO Pharma, focusing on the development of an oral drug targeting STAT6, which has potential applications in treating various inflammatory diseases. As part of the agreement, Gilead will pay LEO Pharma $250 million upfront to license the drug. This collaboration aims to accelerate the development of the STAT6 program, which is expected to address unmet medical needs in the field of inflammatory diseases.
View original story
Similar markets
None • 25%
China • 25%
European Union • 25%
United States • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
United States • 25%
China • 25%
Other • 25%
European Union • 25%
Other • 25%
United States • 25%
Japan • 25%
European Union • 25%
Other • 25%
United Kingdom • 25%
European Union • 25%
Australia • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Other • 25%
Japan • 25%
Canada • 25%
European Union • 25%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
Other • 25%
South Africa • 25%
Asia-Pacific • 25%
European Union • 25%
United States • 25%
Other regions • 25%
United States • 25%
Japan • 25%
Other • 25%
European Union • 25%
Approved in UK and EU • 25%
Not approved in any major market • 25%
Approved in UK, EU, and USA • 25%
Approved in UK only • 25%